

Supporting Information

Identification and optimisation of novel inhibitors of the Polyketide synthase 13 thioesterase domain with antitubercular activity

Simon R. Green^{†*}, Caroline Wilson[†], Thomas C. Eadsforth[†], Avinash S. Puneekar[†], Fabio K. Tamaki[†], Gavin Wood[†], Nicola Caldwell[†], Barbara Forte[†], Neil R. Norcross[†], Michael Kiczun[†], John M. Post[†], Eva Maria Lopez-Román[‡], Curtis A. Engelhart[‡], Iva Lukac[†], Fabio Zuccotto[†], Ola Epemolu[†], Helena I. M. Boshoff[†], Dirk Schnappinger[‡], Chris Walpole[‡], Ian H. Gilbert[†], Kevin D. Read[†], Paul G. Wyatt[†] and Beatriz Baragaña^{†*}

[†]Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, DD1 5EH, UK

[‡]Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY, 10065, USA

[‡]Global Health Medicines R&D, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, 28760, Madrid, Spain

[†]Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, NIAID, NIH, 9000 Rockville Pike, Bethesda, MD, 20892, USA

[‡]Structural Genomics Consortium, Research Institute of the McGill University Health Centre, 1001 Boulevard Décarie, Site Glen Block E, ES1.1614, Montréal, QC H4A 3J1, Canada

***Corresponding Author Information:**

S.R.Green@dundee.ac.uk

b.baragana@dundee.ac.uk


Table of Contents

Title Page	S1
Table S1: Crystal data collection and refinement statistics.	S2
Supplemental Figure 1: Pks13 binding pocket overlays for compounds 50 , 14 & 33 .	S3
Supplemental Figure 2: Dose response curves for compounds 50 , 14 , 15 & 33 tested against a tet-regulated Pks13 strain	S3
Representative <i>in vivo</i> and <i>in vitro</i> compound HPLC UV traces:	S4


Table S1: Crystal data collection and refinement statistics.

	Pks13-TE:50	Pks13-TE:33	Pks13-TE:14
PDB ID	8Q0T	8Q0U	8Q17
Data Collection			
Space group	P2 ₁ 2 ₁ 2	P2 ₁ 2 ₁ 2	P2 ₁ 2 ₁ 2
Cell dimensions			
a, b, c (Å)	88.3, 110.2, 57.9	87.6, 108.6, 57.5	88.4, 109.8, 57.6
α, β, γ (°)	90, 90, 90	90, 90, 90	90, 90, 90
Resolution (Å)	88.27-1.80 (1.84-1.80)	68.17 - 1.8 (1.84 - 1.8)	84.51 - 1.71 (1.77 - 1.71)
Total reflections	364265 (22465)	344236 (18163)	112784 (6923)
Unique reflections	51471 (3078)	48490 (3026)	56541 (3520)
Redundancy	7.1 (7.3)	7.1 (6.0)	11.6 (7.5)
Completeness (%)	97.1 (99.9)	93.8 (100)	92.0 (54.5)
<i>I</i> / <i>σ</i> <i>I</i>	12.6 (1.6)	4.1 (1.3)	12.6 (1.1)
Wilson B-factor	23.3	21.42	24.131
<i>R</i> _{merge}	0.096 (1.109)	0.301 (1.128)	0.112 (1.991)
<i>R</i> _{meas}	0.11 (1.281)	0.349 (1.352)	0.118 (2.140)
CC _{1/2}	0.999 (0.625)	0.93 (0.540)	0.995 (0.764)
Refinement			
Resolution (Å)	1.80	1.80	1.71
No. of reflections	48824 (3627)	45754 (3565)	55847 (3500)
No. of reflections as <i>R</i> _{free}	2565 (202)	2430 (195)	2724 (195)
<i>R</i> _{work} / <i>R</i> _{free} (%)	18.6 / 22.4	18.9 / 23.5	19.53 / 23.87
<i>No. of non-hydrogen atoms</i>			
Protein	4298	4323	4351
Ligand	60	68	118
Water	301	444	340
<i>B</i> -factors (Å ²)			
Average	32.106	30.259	34.15
Protein	32.05	29.69	33.40
Ligand	26.81	43.44	45.41
Water	34.09	39.17	38.29
<i>R.M.S. deviations</i>			
Bond lengths (Å)	0.0183	0.0179	0.0196
Bond angles (°)	1.80	1.86	1.97
Clashscore	N/A	5.14	2.98
<i>Ramachandran Plot</i>			
Favoured (%)	98.33	97.94	97.8
Allowed (%)	1.48	1.87	2.0
Outliers (%)	0.19	0.19	0.19

A




B



Supplemental Figure 1: Pks13 binding pocket overlays for compounds 50, 14 & 33.

Superimposition of the crystal structures of Pks13-50 (PDB ID 8Q0T: yellow and green) and 14 (PDB ID 8Q17: cyan) showing the carbonyl oxygen of the azetidine making an extra direct hydrogen bond interaction (dashed red line) between the side chain of His1664, replacing a water molecule previously bound in the 50 structure (A). A similar binding mode is seen in the crystal structure comparison of Pks13-33 (PDB ID 8Q0U: purple), with an additional hydrogen bond formed between the cyano group and side chain of Asn1640 (B).




Supplemental Figure 2: Dose response curves for compounds 50, 14, 15 & 33 tested against a tet-regulated Pks13 strain

Growth in the presence of anhydrotetracycline (ATc) results in modest transcriptional overexpression of *pks13* while removal of ATc results in transcriptional repression of *pks13* expression. Growth in the presence of compounds is shown relative to DMSO treated samples. Data are representative of two independent experiments.


HPLC Traces

In-vivo compounds


15



44




80




Representative In-vitro compounds


16




17




101




61




62




63




64




65




66



67



3



45

